✓ Translated by DotMD AI Clinical Council Source: JACC. Clinical electrophysiology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #42159524 ↗

Randomized Controlled Trial: The Liraglutide Effects in Atrial Fibrillation (LEAF) Study (N = 28)

Original Paper Title: “The Liraglutide Effects in Atrial Fibrillation (LEAF) Study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 28
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Whereas adding liraglutide to RFM in obese patients with AF did not produce significant differences in early weight loss or LAEAT reduction, improved freedom from AF/atrial flutter was noted.
  • Study Design & Sample: Randomized Controlled Trial published in JACC. Clinical electrophysiology (N = 28 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in JACC. Clinical electrophysiology (2026), this randomized controlled trial evaluating 28 human participants investigated: Atrial fibrillation (AF) ablation continues to offer mediocre outcomes, particularly for persistent AF. Key clinical takeaway: Whereas adding liraglutide to RFM in obese patients with AF did not produce significant differences in early weight loss or LAEAT reduction, improved freedom from AF/atrial flutter was noted.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (JACC. Clinical electrophysiology, 2026-09-15; N = 28; Rigor 82/100): Whereas adding liraglutide to RFM in obese patients with AF did not produce significant differences in early weight loss or LAEAT reduction, improved freedom from AF/atrial flutter was noted.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: liraglutide → Condition: dilated-cardiomyopathy → Condition: familial-genetic-dilated-cardiomyopathy →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42159524: Randomized Controlled Trial: The Liraglutide Effects in Atrial Fibrillation (LEAF) Study (N = 28)

3 of 3 Free Questions Remaining